Stock MPH MEDICURE INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Medicure Inc.

Equities

MPH

CA58469E4085

Biotechnology & Medical Research

Delayed Toronto S.E.
Other stock markets
 11:23:15 2024-04-29 am EDT 		5-day change 1st Jan Change
1.07 CAD +7.00% Intraday chart for Medicure Inc. +8.08% -23.57%
Apr. 09 Transcript : Medicure Inc., 2023 Earnings Call, Apr 09, 2024
Apr. 08 Medicure Swung to a Loss in 2023 on Lower Sales MT

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 95.56 47.54 12.44 9.431 10.35 14.61
Enterprise Value (EV) 1 23.67 35.66 11.17 6.906 6.346 8.786
P/E ratio 25.6 x -3.33 x -1.86 x -13 x 7.71 x -15.6 x
Yield - - - - - -
Capitalization / Revenue 3.28 x 2.36 x 1.07 x 0.43 x 0.45 x 0.67 x
EV / Revenue 0.81 x 1.77 x 0.96 x 0.32 x 0.28 x 0.4 x
EV / EBITDA -25.5 x -5.49 x -2.18 x 19.1 x 2.21 x 9.42 x
EV / FCF 0.37 x -1.56 x 2.66 x 6.01 x 4.87 x 3.73 x
FCF Yield 270% -64% 37.6% 16.6% 20.5% 26.8%
Price to Book 1.14 x 1.76 x 0.64 x 0.51 x 0.49 x 0.73 x
Nbr of stocks (in thousands) 15,538 10,804 10,451 10,251 10,251 10,436
Reference price 2 6.150 4.400 1.190 0.9200 1.010 1.400
Announcement Date 4/29/19 4/16/20 4/20/21 4/27/22 4/6/23 4/8/24
1CAD in Million2CAD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 29.11 20.17 11.61 21.74 23.06 21.69
EBITDA 1 -0.927 -6.501 -5.132 0.361 2.873 0.933
EBIT 1 -1.226 -8.147 -7.686 -2.495 1.193 -0.854
Operating Margin -4.21% -40.39% -66.2% -11.47% 5.17% -3.94%
Earnings before Tax (EBT) 1 4.823 -19.64 -6.845 -0.759 1.385 -0.897
Net income 1 3.926 -19.79 -6.845 -0.727 1.365 -0.922
Net margin 13.49% -98.08% -58.96% -3.34% 5.92% -4.25%
EPS 2 0.2400 -1.320 -0.6406 -0.0709 0.1310 -0.0900
Free Cash Flow 1 63.92 -22.83 4.2 1.15 1.303 2.353
FCF margin 219.58% -113.19% 36.18% 5.29% 5.65% 10.85%
FCF Conversion (EBITDA) - - - 318.49% 45.37% 252.18%
FCF Conversion (Net income) 1,628.22% - - - 95.49% -
Dividend per Share - - - - - -
Announcement Date 4/29/19 4/16/20 4/20/21 4/27/22 4/6/23 4/8/24
1CAD in Million2CAD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 - - - - - -
Net Cash position 1 71.9 11.9 1.27 2.53 4.01 5.83
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 63.9 -22.8 4.2 1.15 1.3 2.35
ROE (net income / shareholders' equity) 4.78% -35.8% -29.7% -3.87% 6.93% -4.51%
ROA (Net income/ Total Assets) -0.66% -6.97% -12.6% -4.99% 2.56% -1.84%
Assets 1 -596 283.8 54.39 14.56 53.37 50.06
Book Value Per Share 2 5.380 2.490 1.870 1.800 2.050 1.910
Cash Flow per Share 2 1.550 1.200 0.2600 0.3600 0.4700 0.6100
Capex 1 0.2 0.19 0 0.38 0.01 -
Capex / Sales 0.68% 0.92% 0.02% 1.73% 0.06% -
Announcement Date 4/29/19 4/16/20 4/20/21 4/27/22 4/6/23 4/8/24
1CAD in Million2CAD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Bio Therapeutic Drugs

1st Jan change Capi.
MEDICURE INC. Stock Medicure Inc.
-23.57% 8.12M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-1.48% 104B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+6.94% 97.47B
ARGENX SE Stock argenx SE
+5.71% 22.25B
BIONTECH SE Stock BioNTech SE
-13.12% 21.68B
GENMAB A/S Stock Genmab A/S
-9.70% 18.2B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-39.98% 17.02B
BEIGENE, LTD. Stock BeiGene, Ltd.
-9.90% 16.36B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+8.17% 14.39B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+38.91% 12.37B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. MPH Stock
  4. Financials Medicure Inc.